XOMA (US) LLC
28
0
0
18
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
32.1%
9 terminated/withdrawn out of 28 trials
66.7%
-19.8% vs industry average
25%
7 trials in Phase 3/4
0%
0 of 18 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (28)
An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass Surgery
Role: lead
Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies
Role: collaborator
A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism
Role: lead
Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment
Role: lead
An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
Role: lead
An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
Role: lead
A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum
Role: lead
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
Role: lead
Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum
Role: lead
The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease
Role: lead
Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Active, Stable, Moderate to Severe Rheumatoid Arthritis
Role: lead
Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
Role: lead
An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data
Role: lead
Open-label Safety Extension Study of Gevokizumab in Erosive Osteoarthritis of the Hand
Role: lead
Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand
Role: lead
Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris
Role: lead
Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well Controlled Type 1 Diabetes
Role: lead
Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand
Role: lead
Effects of XOMA 052 on Insulin Production in Type 1 Diabetes
Role: collaborator
Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy
Role: collaborator